Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital58 Merck Sharp & Dohme LLC36 Anhui Medical University29 AstraZeneca26 Eli Lilly and Company25
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Hefei

896 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
Anhui Provincial Children's Hospital
Observational
500
Hefei
2024-11-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NCT06714708NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
Anhui Provincial Cancer Hospital
Phase 2
86
Hefei
2024-11-20
Recruiting
Anhui Provincial Hospital
Phase 2
60
Fuyang, Hefei
2024-11-16
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Ma’anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
Anhui Provincial Hospital
Phase 2
60
Fuyang, Hefei
2024-11-10
Recruiting
Keymed Biosciences Co.Ltd
Phase 1
48
Hefei
2024-11-08
Not yet open
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou
2024-11-07
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Active, closed
Neuroimage-guided Dual-target Continuous Theta Burst Stimulation for Generalized Anxiety Disorder
NCT06699706Anxiety, Transcranial Magnetic Stimulation Repetitive
Anhui Medical University
Not applicable
60
Hefei
2024-11-01
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
590
Hefei
2024-10-28
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Recruiting
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Ha’erbin, Wuhan, Xiangyang
2024-10-22
Recruiting
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Not applicable
60
Hefei
2024-10-21
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Recruiting
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
Recruiting
Anhui Provincial Hospital
Observational
150
Hefei
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
560
Hefei
2024-10-02
By invitation
Anhui Medical University
Not applicable
30
Hefei
2024-10-01
By invitation
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-09-26
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Active, closed
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
99
Hefei, Fuzhou, Quanzhou, Xiamen, Zhangzhou, Shanghai, Hangzhou
2024-09-11
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
By invitation
Anhui Medical University
Observational
600
Hefei
2024-09-01
By invitation
The Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) Targeting the Right Globus Pallidus Internus (GPi) for Motor Symptoms in Patients With PD
NCT06931483Temporal Interference Stimulation, Parkinson's Disease, the Right Globus Pallidus Internus, Motor Symptoms
Yanghua Tian
Not applicable
40
Hefei
2024-09-01
Recruiting
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
NCT06642025Acute Myeloid Leukemia (AML), CAR-T
Zhimin Zhai
Early Phase 1
9
Hefei
2024-09-01
Recruiting
Anhui Provincial Hospital
Observational
318
Hefei
2024-08-15
Recruiting
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Active, closed
Wan-Jin Chen
Phase 3
928
Hefei, Taihe Chengguanzhen, Wuhu, Anxi, Fuqing, Fuzhou, Longyan, Nanping
2024-08-01
By invitation
Clinical Efficacy and Mechanism of rTMS Based on dlPFC in the Intervention of Generalized Anxiety Disorder With Insomnia
NCT06931236Generalized Anxiety Disorder (GAD), Insomnia, Repetitive Transcranial Magnetic Stimulation (rTMS)
Yanghua Tian
Not applicable
30
Hefei
2024-08-01
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Recruiting
JIANGSU SHENMING Medical Technology CO., Ltd
Not applicable
216
Hefei, Beijing, Nanning, Guiyang, Shijiazhuang, Anyang, Luoyang, Zhengzhou
2024-07-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
Anhui Provincial Hospital
Phase 2
45
Fuyang, Hefei
2024-07-20
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Active, closed
Vor Biopharma
Phase 3
191
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
DrugColchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Active, closed
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Active, closed
Tianjin Medical University General Hospital
Phase 2/3
102
Hefei, Lanzhou, Shijiazhuang, Harbin, Zhenzhou, Ordos, Changzhou, Suzhou
2024-07-09
Not yet open
Anhui Provincial Hospital
Phase 2
39
Hefei
2024-07-01
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Not applicable
66
Hefei, Zhengzhou, Nanjing, Beijing
2024-07-01
Recruiting
Anhui Provincial Hospital
Phase 1/2
45
Hefei
2024-07-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Recruiting
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
NCT06449937Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
Anhui Provincial Hospital
Not applicable
130
Chuzhou, Fuyang, Hefei, Ma’anshan, Wuhu
2024-07
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Active, closed
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
By invitation
Anhui Provincial Hospital
Phase 1
9
Hefei
2024-06-21
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Active, closed
Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer
NCT06527001Progression-Free Survival, Overall Survival, Nutrition Aspect of Cancer
Anhui Provincial Hospital
Observational
300
Hefei
2024-06-16
Recruiting
Oupushifang Pharmaceutical Technology Co., Ltd.
Phase 3
606
Hefei, Xuancheng, Lanzhou, Liuzhou, Nanning, Guiyang, Zunyi, Daqing
2024-06-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Active, closed
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an
2024-06-11
Active, closed
GlaxoSmithKline
Phase 3
88
Chengdu, Hangzhou, Hefei, Nanjing, Shanghai
2024-06-10
Recruiting
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
DrugHenagliflozin
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium
Peking University First Hospital
Not applicable
3,992
Chizhou, Hefei, Ma’anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin
2024-05-29
Recruiting
Anhui Provincial Hospital
Not applicable
450
Hefei
2024-05-28
Recruiting
The Affiliated Hospital Of Guizhou Medical University
Not applicable
396
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili
2024-05-27
Recruiting
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
Anhui Provincial Cancer Hospital
Phase 2
74
Hefei
2024-05-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2/3
90
Hefei, Fuzhou, Shanghai, Ningbo
2024-05-21
Recruiting
IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NCT06118840Intracranial Aneurysm, CT Angiography, Deep Learning, Double Bind Interaction
Jinling Hospital, China
Not applicable
6,450
Hefei, Wuhu, Guiyang, Zhengzhou, Shiyan, Nanjing, Xuzhou, Changchun
2024-05-20
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06395870B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital
Phase 1
33
Hefei, Tianjin
2024-05-09
Recruiting
Hutchmed
Phase 2/3
502
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong
2024-05-08
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
65
Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai
2024-05-07
Not yet open
Anhui Provincial Hospital
Phase 1
9
Hefei
2024-05-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Recruiting
Anhui Provincial Hospital
Phase 2
30
Hefei
2024-05-01
Recruiting
Cervical Cancer Susceptible Population Classification
NCT06405945Cervical Cancer Susceptible Population Classification
Anhui Provincial Hospital
Observational
10,000
Hefei
2024-05-01
Recruiting
Anhui Provincial Cancer Hospital
Phase 1/2
28
Hefei
2024-05-01
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugBirelentinib
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Active, closed
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
Simcere Pharmaceutical Co., Ltd
Phase 2
226
Fuyang, Hefei, Huangshan City, Guangzhou, Wuzhou, Shijiazhuang, Zhumadian, Nanchang
2024-04-08
Recruiting
Early Pancreatic Stent Placement for Preventing PEP
NCT06250803Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis
The First Affiliated Hospital of Anhui Medical University
Not applicable
768
Hefei
2024-04-01
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Recruiting
Anhui Provincial Hospital
Early Phase 1
9
Hefei, Wuhan
2024-03-15
Recruiting
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2
94
Hefei, Zhengzhou, Changsha, Nanjing, Shanghai, Linhai
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Recruiting
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
DrugsIdarubicin Hydrochloride·Granulocyte Colony-Stimulating Factor·Avapritinib·Decitabine
Children's Hospital of Soochow University
Phase 2
50
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-03-01
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
98
Hefei, Shanghai
2024-03-01
Recruiting
A Study Assessing the Effects of Acupuncture in Parkinson's Disease Patients With Chronic Appendicitis
NCT06304285Parkinson's Disease, Chronic Appendicitis, Acupuncture
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
84
Hefei
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Recruiting
Anhui Provincial Hospital
Observational
25
Hefei
2024-03-01
Active, closed
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Recruiting
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Hefei, Hangzhou, Wenzhou, Beijing
2024-02-23
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Hefei, Fuzhou, Foshan, Guangzhou, Jiangmen, Nanning, Luoyang, Zhengzhou
2024-02-21
Recruiting
Anhui Provincial Hospital
Not applicable
12
Hefei
2024-02-10
Recruiting
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Active, closed
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Active, closed
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Active, closed
DualityBio Inc.
Phase 3
541
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-01-18
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
50
Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen
2024-01-13
Recruiting
Daiichi Sankyo
Phase 3
75
Changchun, Harbin, Hefei
2024-01-05
Recruiting
Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion
NCT06155032Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive
First Affiliated Hospital of Wannan Medical College
Not applicable
272
Fuyang, Hefei, Huainan, Huangshan City, Suzhou, Wuhu, Xiangyang
2024-01-04
Recruiting
A Study of TYK-00540 in Adult Patients With Solid Tumors
NCT06246071Locally Advanced or Metastatic Solid Tumors
DrugTYK-00540
TYK Medicines, Inc
Phase 1
156
Hefei
2024-01-02
Recruiting
Anhui Provincial Hospital
Not applicable
70
Hefei
2024-01-01
Not yet open
Hospital Affiliated to the Institute of Neurology, Anhui University of Chinese Medicine
Observational
200
Hefei
2024-01-01
Recruiting
Children's Hospital of Soochow University
Phase 2
500
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-01-01
Recruiting
Central South University
Observational
2,000
Hefei, Zhengzhou, Changsha, Nanjing
2024-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Recruiting
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Active, closed
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
DrugHS-20089
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Not yet open
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xi’an
2023-12-01
Recruiting
An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy
NCT06151028Gynecological Malignancies, Menopausal Symptoms, Bone Loss
Anhui Provincial Hospital
Observational
490
Hefei
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Not yet open
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang
2023-11-11
Recruiting
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
NCT07130565Amyloid, Cardiac Amyloidosis, Amyloidosis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2023-11-01
Active, closed
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
NCT06480617Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Anhui Provincial Hospital
Observational
3,000
Hefei
2023-10-31
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen
2023-10-09
Recruiting
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
NCT06092047CD19-positive Relapsed or Refractory B-cell Malignancies
DrugsFludarabine·Cyclophosphamide
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1
10
Hefei
2023-10-01
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
52
Hefei, Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Xiangyang
2023-09-19
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Hefei, Beijing, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2023-09-14
Recruiting
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
DrugFWD1802
Forward Pharmaceuticals Co., Ltd.
Phase 1/2
99
Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan
2023-09-12
Recruiting
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
NCT06030804Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors
DrugDexmedetomidine
Peking University First Hospital
Not applicable
4,532
Hefei, Beijing, Chongqing, Fuzhou, Jinjiang, Guangzhou, Shenzhen, Nanning
2023-09-12
Recruiting
Gilead Sciences
Phase 3
402
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei
2023-09-07
Recruiting
Anhui Provincial Hospital
Phase 1/2
70
Hefei
2023-09-01
Not yet open
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
550
Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing
2023-09-01
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Recruiting
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Active, closed
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124Primary Biliary Cholangitis (PBC)
DrugPleacbo
Cascade Pharmaceuticals, Inc
Phase 2
75
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun
2023-08-07
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Recruiting
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Active, closed
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Xiang Yang Zhang
Not applicable
50
Hefei, Beijing
2023-08-01
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan
2023-07-06
Recruiting
Anhui Provincial Hospital
Observational
70
Hefei
2023-07-01
Recruiting
Anhui Medical University
Early Phase 1
1,084
Hefei
2023-07
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Active, closed
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Recruiting
Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
NCT07041320Lung Cancer (NSCLC), Elderly (People Aged 65 or More)
Anhui Chest Hospital
Observational
40
Hefei
2023-06-15
Active, closed
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Active, closed
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
Recruiting
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Recruiting
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
NCT05823376Platelet Recovery After Umbilical Cord Blood Transplantation
DrugAvatrombopag
Anhui Provincial Hospital
Observational
40
Hefei
2023-05-04
Not yet open
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Recruiting
Anhui Medical University
Not applicable
40
Hefei
2023-05-01
Active, closed
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Qilu Hospital of Shandong University
Phase 4
2,600
Bozhou, Chuzhou, Hefei, Beijing, Zunyi, Zhengzhou, Dalian, Xining
2023-04-12
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
40
Hefei
2023-04-01
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Active, closed
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Not yet open
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Active, closed
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Active, closed
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06198413Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 1
12
Hefei, Hangzhou, Shanghai
2023-02-27
Active, closed
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Recruiting
Shanghai Tong Ren Hospital
Phase 2
58
Changzhou, Chengdu, Ch’ang-ch’un, Ha’erbin, Hefei, Jiaxing, Lanzhou, Ningbo
2023-02-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan
2023-02-14
Active, closed
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Recruiting
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Recruiting
Real-world Study Optimizing Nucleotide-analogues
NCT05937178Hepatitis B, Chronic
Huashan Hospital
Observational
20,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang
2023-01-31
Active, closed
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Recruiting
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Active, closed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Active, closed
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104Moderate to Severe Ulcerative Colitis
DrugMufemilast
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
92
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2022-11-08
Active, closed
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038Basilar Artery Occlusion, Endovascular Treatment
Beijing Tiantan Hospital
Not applicable
338
Hefei, Beijing, Anyang, Zhangzhou, Baotou
2022-11-07
Recruiting
Bai-Rong Xia
Phase 2
37
Hefei
2022-11-06
Recruiting
Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
NCT06336174Intracranial Atherosclerosis, Cognitive Impairment, Cerebrovascular Event
Anhui Medical University
Observational
100
Hefei
2022-11-01
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
470
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha
2022-10-26
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
DrugSonrotoclax
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Active, closed
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Zhengzhou, Wuhan
2022-09-05
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Active, closed
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
China HEalthy Aging and Dementia Study (HEAD)
NCT07912710Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
Fudan University
Observational
20,000
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan
2022-08-01
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Recruiting
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Active, closed
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsOlaparib·Bevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Active, closed
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
The First Affiliated Hospital of Anhui Medical University
Phase 2
50
Hefei
2022-06-01
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Active, closed
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Active, closed
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
By invitation
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Recruiting
FAPI PET/CT in Various FAP-Related Disease Patients
NCT06688071FAP-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2022-03-01
Recruiting
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT06690736CXCR4-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Not applicable
200
Hefei, Qingdao, Tianjin
2022-03-01
Active, closed
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Recruiting
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
DrugSPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Early Phase 1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Recruiting
Genor Biopharma Co., Ltd.
Phase 3
350
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan
2022-01-14
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Recruiting
Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait
NCT05192759Transcranial Magnetic Stimulation, Freezing of Gait
Anhui Medical University
Not applicable
40
Hefei
2021-11-22
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Active, closed
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Recruiting
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Active, closed
Zhigang Li
Phase 3
426
Shanghai, Anyang, Guangzhou, Hefei
2021-09-01
Not yet open
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
102
Chongqing, Fuzhou, Ganzhou, Hangzhou, Harbin, Hefei, Mianyang, Nanjing
2021-08-31
Active, closed
Akeso
Phase 3
445
Hangzhou, Hefei, Shanghai
2021-08-27
Active, closed
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Active, closed
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Active, closed
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
DrugHuaier
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Active, closed
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
2,500
Hefei, Beijing, Chongqing, Xianmencun, Dongguan, Guangzhou, Shenzhen, Zhuhai
2021-06-02
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Active, closed
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Active, closed
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Active, closed
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
6,642
Hefei, Zhoukou, Tai’an, Tianjin
2021-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
84
Hefei, Yantai, Shanghai, Hangzhou
2021-01-01
Active, closed
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
120
Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei
2020-12-25
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Active, closed
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Bayer
Phase 3
774
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Active, closed
AbbVie
Phase 3
527
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2020-09-30
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Recruiting
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
NCT06690970PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2020-09-01
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
648
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2020-08-11
Active, closed
Eli Lilly and Company
Phase 3
996
Hefei, Chongqing, Xiamen, Foshan, Guangzhou, Wuhan, Changsha, Changzhou
2020-06-22
Active, closed
AstraZeneca
Phase 2
452
Chengdu, Guangzhou, Hefei, Shanghai, Shenyang, Wuhan, Zhengzhou
2020-06-03
Active, closed
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou
2020-02-11
Active, closed
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Active, closed
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
690
Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou
2019-10-01
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Active, closed
Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
NCT03977129Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Ruijin Hospital
Not applicable
792
Hefei, Fuzhou, Zhengzhou, Changsha, Jinan, Qingdao, Shanghai, Tianjin
2019-08-04
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou
2019-07-15
Active, closed
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
Active, closed
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Recruiting
AstraZeneca
Phase 3
140
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Hefei, Shanghai
2019-04-02
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Recruiting
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957SSTR-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2019-02-01
Recruiting
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
NCT06725693GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2019-02-01
Recruiting
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Recruiting
Anhui Provincial Hospital
Observational
467
Hefei
2019-01-01
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
Eli Lilly and Company
Phase 2/3
393
Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha
2018-11-26
Recruiting
Translocator Protein PET/CT in Various TSPO-Related Disease
NCT06725719Neuroinflammation, Stroke, Neurodegenerative Diseases
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2018-11-01
Active, closed
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Recruiting
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Active, closed
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Active, closed
3D Medicines (Sichuan) Co., Ltd.
Phase 2
188
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2018-08-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guanghzou, Guangzhou, Guiyang
2018-08-21
Recruiting
Tau PET/CT in Various Tau-Related Disease Patients
NCT06690983Tauopathies, Neurodegenerative Diseases, Neurodegeneration
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2018-08-01
Active, closed
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
BeiGene
Phase 3
224
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Harbin, Zhengzhou
2018-05-14
Active, closed
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Active, closed
BeiGene
Phase 3
590
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Zhengzhou, Wuhan
2017-10-31
Active, closed
AbbVie
Phase 2
66
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2017-10-12
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
DrugVedolizumab
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Active, closed
AstraZeneca
Phase 3
1,186
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2017-06-01
Active, closed
AstraZeneca
Phase 3
987
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Hangzhou, Hefei
2017-03-27
Recruiting
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
NCT07830576Colorectal Liver Metastases, Colorectal Neoplasms, Liver Neoplasms
Anhui Provincial Hospital
Observational
205
Hefei
2017-02-01
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2016-09-13
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangong Apt/Yuncheng, Hangzhou, Hefei
2016-05-24
Active, closed
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Recruiting
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
NCT07379463Amino-Acid Transport Disorder, Primary Hyperparathyroidism, Glioma
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2013-08-29
Recruiting
Beta Amyloid PET/CT in Various Aβ-Related Disease
NCT06725706Amyloid, Beta-Amyloid, Neurodegenerative Diseases
Tianjin Medical University
Observational
500
Hefei, Beijing, Qingdao, Tianjin
2012-09-01
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Nanning, Chengdu, Beijing, Dalian, Guangzhou, Hangzhou, Harbin, Hefei
2012-01
Recruiting
The Chinese Familial Alzheimer's Network
NCT03657732Alzheimer Disease, Familial Alzheimer Disease (FAD)
Capital Medical University
Observational
40,000
Hefei, Changping, Chaoyang, Fengtai, Haidian, Xicheng, Yuzhong, Fujian
2005-01-10
Recruiting
China Cognition and Aging Study
NCT03653156Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
Capital Medical University
Observational
100,000
Hefei, Changping, Chaoyang, Fengtai, Haidian, Xicheng, Yuzhong, Fujian
2000-01-01
Recruiting
Medtronic
Observational
20,000
Beijing, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
1983-01
Rows per page Showing 501–896 of 896
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/hefei?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 896 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

537 of the 896 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 135 have not yet opened recruitment, 210 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.